

## HALT-IT TRIAL: 9,000 patients randomised



### To our **COLLABORATORS:**

Congratulations to you all for working tirelessly for the success of our trial. You have recruited **9,000** patients. This has only been possible due to the drive and dedication of all the collaborating teams. It has been wonderful to witness your interest and enthusiasm for the trial. Summer is finally here and the spirits here at the TCC are noticeably lifting! Our challenge is now to recruit **12,000** patients by the end of **May 2019**.



**Hospital Universiti Sains  
Malaysia**



**Emergency County Hospital  
Mures, Romania**



**Musgrove Park Hospital,  
United Kingdom**



**University of Benin  
Teaching Hospital, Nigeria**



**Aziz Bhatti Shaheed Teaching  
Hospital, Pakistan**

**RECRUITMENT UPDATE:** FINAL YEAR to recruit the last 3,000 patients with 15 countries recruiting in 162 sites; the number increasing every day!

# HALT-IT RECRUITMENT



Liaquat University of Medical and Health Sciences (LUMHS) Medical Unit II, Pakistan

# TEAM

Together everyone achieves more.



## New sites awaiting recruitment:

- University of Nigeria Teaching Hospital, Enugu, Nigeria
- Prince Mohammed Bin Abdulaziz Hospital (PMAH), Saudi Arabia
- Jinnah Postgraduate Medical Centre Karachi, Pakistan
- Federal Medical Centre - Abeokuta, Nigeria
- Emergency County Hospital Mures, Romania
- University of Abuja Teaching Hospital, Nigeria

**WHO WILL RECRUIT FIRST?!**



# TOP RECRUITER

*Congratulations*




Kasr Al Aini Internal Medicine Hospital, Egypt

**416 PATIENTS RECRUITED AT KASR AL-AINI**



# GLOBAL RECRUITMENT



**9000 PATIENTS**




Hayatabad Medical Complex, Pakistan



Asian Institute of Medical Sciences, Pakistan



Royal Infirmary of Edinburgh, UK



PI of DHQ Sargodha, Pakistan



Darlington Memorial Hospital, UK

# MEET OUR GLOBAL COLLABORATORS...



**Madinah Teaching Hospital Faisalabad, Pakistan**



**Janaki Medical College Teaching Hospital, Nepal**

“HALT-IT has helped our team to understand the importance of trials in enhancing the academic scenario along with development of team work in a clinical setup. The trial has been conducted internationally in an orderly and planned manner with thousands of patients participating to date. My team and I, at JMC-TH wish the trial a huge success in the near future.”

- Dr Vijay Kumar Sah (PI)



**Cork University Hospital, Ireland**

“...I am so happy to be a member of this excellent network of collaborators who are capable of providing evidence – based answers to a number of critical questions that seriously affect our patients' management. It has become obvious, that to improve patient care, it is not enough to have a personal impression, but an evidence based strategy. We have to work together worldwide to be able to prove or dispute the value or efficacy of a certain intervention. This goal cannot be accomplished by one person. But, by a hard working team dedicated to complete the task over several years.



Personally, I am so proud with the valuable friendships I have gained through joining the HALT-IT trial.

Together, we can help to improve patient care for our nations and for every human being”.

**Dr Hussein Khamis**

- *National Coordinator of Egypt & PI of Mataria Teaching Hospital*



**Bucharest Clinical Emergency Hospital - SCUB Floreasca, Romania**



**Monitoring in Georgia:**

Danielle, Monica and Haleema from the CTU monitoring source data including DRS with PI Tamar Gogichashvili and team at High Technology Medical Centre in Georgia.



**Ibn Sina Hospital, Sudan**



**University Hospital Coventry, UK**



**Colentina Clinical Hospital, Romania**



**Kings Mill Hospital, United Kingdom**



Royal London Hospital, UK



Gloucestershire Royal Hospital, UK



Charing Cross Hospital, UK

Lady Reading Hospital, Pakistan



"The Department of Gastroenterology and Hepatology is one of the largest and purpose built units in KPK Province, in the North West of Pakistan . It caters for a population of nearly 2 million and from across the border of Afghanistan.

Especially with the war on terror going on, and the health services in Afghanistan totally destroyed, patients have been seeking medical attention. All GI bleeds coming to the Hospital are dealt by my team and those patients who fit the HALT-IT protocol are randomised. We are one of the largest contributors of patients to the trial and have so far had excellent support from trial team in London. We look forward to continue collaborating from across the border at Lady Reading Hospital."



Hospital Sultanah Bahiyah, Malaysia



Services Hospital Unit III, Pakistan



Ibn Sina Hospital, Sudan



National Coordinating Centre in Ibadan, Nigeria



University College London, UK



POF Hospital, Pakistan

"We hope the study will go a long way in improving the management of GI bleed especially in the developing world".

## ANY SIGNIFICANT CHANGES TO YOUR TRIAL TEAM?

Please ensure all of your trial team members have been trained and have been added to the **training log** and **site delegation log**.

If key team members change, remember to let the CTU know—we are always here and happy to help with training new members if needed!



Queen Elizabeth Hospital Birmingham, UK

"Here at QEH Birmingham, we have recruited 144 patients through having a strong working relationship with our Emergency Department staff, who alert us to potential patients."



St George's Hospital, UK



St Thomas' Hospital, UK

# And SOME MORE...



University of Ilorin Teaching Hospital, Nigeria



Olabisi Onabanjo University Teaching Hospital, Nigeria

Kasr Al Aini Internal Medicine Hospital, Cairo University

Dr Serag Esmat, MD

- Professor of Internal Medicine and Gastroenterology, Faculty of Medicine



"GI bleeding is a common serious health problem in Egypt especially variceal bleeding due to the high prevalence of chronic liver diseases. HALT-IT trial is very important as it will determine if the administration of Tranexamic Acid for the treatment of GI haemorrhage will improve the outcome or not and if we can add it to the protocol of GI bleeding treatment. Participating in the HALT-IT trial is very interesting to our team. It is a great positive experience to be part of HALT-IT and we are working with true enthusiasm. Recruitment rate at our hospital is high; however, we are facing difficulties in the customs clearance of the trial drug. The HALT-IT team at the TCC are professional and very dedicated. It is great working with them. Moreover, participating in HALT-IT gives our team a considerable experience in clinical research trials."



LET'S WORK TOGETHER  
TEAMWORK



DHQ Hospital Faisalabad, Pakistan



Hospital Raja Permaisuri Bainun, Malaysia



Obafemi Awolowo University Teaching Hospital Ife-Ife, Nigeria



Glasgow Royal Infirmary, UK



"At Glasgow Royal Infirmary, we screen patients who present to the ED, Surgical and Endoscopy units each morning via electronic systems. We have given presentations and updates about HALT-IT to colleagues in these units, together with regular emails to keep the study profile high. With the fantastic help of our team, we have ensured colleagues remain engaged with HALT-IT, to enable us to keep up a steady recruitment of patients."

- Dr Adrian Stanley (PI)



Liaquat National Hospital & Postgraduate Medical Centre, Pakistan



University of Ilorin Teaching Hospital, Nigeria

# NATIONAL MEETING IN PAKISTAN



# NATIONAL MEETING IN NIGERIA




# REMEMBER!



Only patients with significant bleeds should be included in the trial. The diagnosis of significant bleeding is clinical but may include patients with hypotension, tachycardia, or those likely to need transfusion, urgent endoscopy or surgery.

TXA has been shown to reduce death in traumatic bleeding. The CRASH-2 and the WOMAN trials showed that early administration of TXA reduces the risk of death due to bleeding by about one third, with no increase in thromboembolic events. If TXA had similar effects in GI bleeding this would be a major advance.



Our patients are randomised from all over the world. Participating countries are highlighted red on the world map above. A trial like HALT-IT can only succeed as a result of international collaboration.



## Nepal Medical College and Teaching Hospital, Nepal

“HALT-IT is very important in Nepal as Octreotide is used for variceal bleeding and is very expensive in the rural region. TXA is a cheaper and a more widely available alternative. I have enjoyed every part of the trial. Entering the data, conducting meetings and guiding the team is enjoyable. It's a new experience for me and it has helped my career as a researcher and leader, and has enhanced my interest in the field of research!”

*Dr Anuj KC (PI)*



10 months left to recruit the final 3,000 patients - every single patient counts to ensure we reach 12,000 patients!!!